Leukocyte telomere length and renal cell carcinoma survival in two studies
A partir de données de deux études incluant respectivement 684 et 241 patients atteints d'un carcinome à cellules rénales, cette étude évalue l'association entre la longueur des leucocytes des télomères et la survie
Background:Leukocyte telomere length (LTL) is a potential biomarker of cancer prognosis; however, evidence for renal cell carcinoma (RCC) is inconsistent.
Methods : We investigated LTL and RCC-specific survival among 684 cases from the US kidney cancer study (USKC) and 241 cases from the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO). Leukocyte telomere length was measured by quantitative polymerase chain reaction, and hazard ratios (HRs) and 95% confidence intervals (CIs) computed using multivariable Cox models.
Results: Short LTL was associated with poorer disease-specific survival in both USKC (lowest vs highest quartile: HR: 2.3, 95% CI: 1.2–4.4; P for trend=0.02) and PLCO (HR: 2.4, 95% CI: 1.0–5.4; P=0.04). Among USKC cases, the association was strongest for stage-I RCC (HR: 5.5, 95% CI: 1.6–19.0; P=0.006).
Conclusions: Our findings suggest that shorter LTL is an independent marker of poor RCC prognosis, particularly for stage-I disease.
British Journal of Cancer , résumé, 2016